The Platform Group AG Raises 2026 Financial Forecast

The Platform Group AG has increased its 2026 financial forecast, expecting sales to reach EUR 1 billion and EBITDA between EUR 70 and 80 million. This adjustment comes after three significant acquisitions in the pharmaceutical sector, including Pharmosan Group, Vamida mail-order pharmacy, and Apothekia. These acquisitions are projected to contribute over EUR 130 million in sales by 2026. As a result, the “Service & Retail Goods” segment will be rebranded as “Pharma & Service Goods.”

Additionally, The Platform Group has expanded its "Optics & Hearing" segment through agreements to purchase two more companies, which currently generate single-digit million sales with a 24% EBITDA margin. The financial forecast for 2025 remains unchanged, and these transactions await antitrust authority approvals, with closures expected by the end of 2025.